Makary Resigns as FDA Commissioner Following Policy Disputes - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

  • By

  • Kathryn Wighton

  • May 12, 2026

  • 2 min

Share

Objective:

To report on the resignation of FDA Commissioner Marty Makary and the circumstances surrounding his tenure.

Key Findings:
  • Makary's resignation was influenced by policy disputes and tensions with lawmakers and pharmaceutical companies.
  • His tenure was marked by significant public health decisions during the COVID-19 pandemic.
  • He faced criticism from various stakeholders, including anti-abortion lawmakers and biopharmaceutical companies.
Interpretation:

Makary's resignation reflects the complexities and challenges of leading the FDA amid political and public health controversies.

Limitations:
  • The article does not provide detailed insights into the specific reasons behind the policy disputes.
  • Limited information on the impact of Makary's policies on public health outcomes.
Conclusion:

Marty Makary's resignation highlights the contentious nature of FDA leadership and the challenges faced in navigating public health policy.

Original Source(s)

Makary Resigns as FDA Commissioner Following Policy Disputes

  • by Kathryn Wighton

  • May 12, 2026

Related Content

CKM staging faces an early vascular test

Investigators examined Life’s Essential 8 scores and carotid ultrasonography measures across cardiovascular-kidney-metabolic stages in 1,283 young adults.

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

FDA approves first therapy for warm autoimmune hemolytic anemia

The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.